CN110840890A - 用于在心力衰竭中控制血压和减轻呼吸困难的方法 - Google Patents

用于在心力衰竭中控制血压和减轻呼吸困难的方法 Download PDF

Info

Publication number
CN110840890A
CN110840890A CN201911070111.9A CN201911070111A CN110840890A CN 110840890 A CN110840890 A CN 110840890A CN 201911070111 A CN201911070111 A CN 201911070111A CN 110840890 A CN110840890 A CN 110840890A
Authority
CN
China
Prior art keywords
blood pressure
clevidipine
patient
patients
dyspnea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911070111.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·C·小施平德勒
L·M·伊特里
G·C·威廉斯
M-Y·胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN110840890A publication Critical patent/CN110840890A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201911070111.9A 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法 Pending CN110840890A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US61/719,127 2012-10-26
CN201380068074.2A CN104968199A (zh) 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380068074.2A Division CN104968199A (zh) 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法

Publications (1)

Publication Number Publication Date
CN110840890A true CN110840890A (zh) 2020-02-28

Family

ID=50545374

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911070111.9A Pending CN110840890A (zh) 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法
CN201380068074.2A Pending CN104968199A (zh) 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380068074.2A Pending CN104968199A (zh) 2012-10-26 2013-10-26 用于在心力衰竭中控制血压和减轻呼吸困难的方法

Country Status (18)

Country Link
US (1) US10881645B2 (cg-RX-API-DMAC7.html)
EP (1) EP2925128B1 (cg-RX-API-DMAC7.html)
JP (2) JP6329957B2 (cg-RX-API-DMAC7.html)
KR (1) KR102299073B1 (cg-RX-API-DMAC7.html)
CN (2) CN110840890A (cg-RX-API-DMAC7.html)
AU (1) AU2013334081B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015009291B1 (cg-RX-API-DMAC7.html)
CA (1) CA2889584C (cg-RX-API-DMAC7.html)
EA (1) EA030354B1 (cg-RX-API-DMAC7.html)
ES (1) ES2671639T3 (cg-RX-API-DMAC7.html)
IL (1) IL238462A0 (cg-RX-API-DMAC7.html)
MX (1) MX359768B (cg-RX-API-DMAC7.html)
NZ (1) NZ708511A (cg-RX-API-DMAC7.html)
PL (1) PL2925128T3 (cg-RX-API-DMAC7.html)
TR (1) TR201807636T4 (cg-RX-API-DMAC7.html)
UA (1) UA117571C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014066870A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503741B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114966056A (zh) * 2022-06-08 2022-08-30 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385243B (es) * 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
CN102186351A (zh) 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
EP2498731B1 (en) * 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABBIE L. ERICKSON等: "Clevidipine: A Short-Acting Intravenous Dihydropyridine Calcium Channel Blocker for the Management of Hypertension", 《PHARMACOTHERAPY》 *
THE MEDICINES COMPANY,U.S.NIH CLINICAL: "Clevidipine in the treatment of Blood Pressure in patients with acute heart failure(PRONTO) History of change for study NCT00803634", 《网络公开HTTPS://WWW.CLINICALTRALS.GOV/CT2/HISTORY/NCT00803634?V_1=VIEW#STUDYPAGETOP》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114966056A (zh) * 2022-06-08 2022-08-30 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Also Published As

Publication number Publication date
NZ708511A (en) 2018-11-30
BR112015009291B1 (pt) 2021-03-16
CA2889584C (en) 2018-08-14
MX359768B (es) 2018-10-10
EA030354B1 (ru) 2018-07-31
KR20150104084A (ko) 2015-09-14
PL2925128T3 (pl) 2018-10-31
EP2925128A1 (en) 2015-10-07
JP2018065875A (ja) 2018-04-26
EA201590825A1 (ru) 2015-09-30
EP2925128A4 (en) 2016-06-08
IL238462A0 (en) 2015-06-30
CN104968199A (zh) 2015-10-07
ZA201503741B (en) 2022-09-28
AU2013334081A1 (en) 2015-06-11
BR112015009291A2 (pt) 2017-07-04
AU2013334081B2 (en) 2017-05-18
US10881645B2 (en) 2021-01-05
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
KR102299073B1 (ko) 2021-09-09
TR201807636T4 (tr) 2018-06-21
US20140121247A1 (en) 2014-05-01
JP6329957B2 (ja) 2018-05-23
EP2925128B1 (en) 2018-04-11
WO2014066870A1 (en) 2014-05-01
UA117571C2 (uk) 2018-08-27
MX2015005341A (es) 2016-05-24
ES2671639T3 (es) 2018-06-07

Similar Documents

Publication Publication Date Title
EP3607962B1 (en) Angiotensin ii alone or in combination for the treatment of hypotension
Khilnani et al. Non-invasive ventilation after extubation in patients with chronic obstructive airways disease: a randomised controlled trial
US10987332B2 (en) Sprayable aqueous composition comprising glyceryl trinitrate
US20250213504A1 (en) Methods of intravenously administering sotalol hydrochloride for the treatment of pediatric patients
AU2013334081B2 (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
Tommaso et al. Atrial fibrillation and flutter: immediate control and conversion with intravenously administered verapamil
US20050255096A1 (en) Combination treatment for acute myocardial infarction
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
EP3701956B1 (en) Prophylactic and/or therapeutic agent for dementia
US20040037896A1 (en) Therapeutic treatment
Verrill et al. Vasovagal faint in the supine position
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
Mimran et al. Maintenance of the antihypertensive efficacy of captopril despite consistent reduction in daily dosage.
KR101296479B1 (ko) 심혈관 질환 치료를 위한 l-카르니틴 및 글루코오스의용도
Haque et al. Epinephrine in Paediatric Clinical Practice-Clinical Update
Tamargo et al. Class III Antiarrhythmic
US20070244101A1 (en) Novel compositions and methods of treatment of type ii diabetes and hypertension
TAKAHASHI et al. Y YAZAKI
NZ543221A (en) Anti-rotation foot for strainer post

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020897

Country of ref document: HK